Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05298995
Other study ID # GD2CAR02
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date November 9, 2023
Est. completion date November 2038

Study information

Verified date November 2023
Source Bambino Gesù Hospital and Research Institute
Contact Francesca Del Bufalo, MD
Phone 00396859
Email francesca.delbufalo@opbg.net
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to test the safety and efficacy of iC9-GD2-CAR T-cells, a third generation (4.1BB-CD28) CAR T cell treatment targeting GD2 in paediatric or young adult patients affected by relapsed/refractory malignant central nervous system (CNS) tumors. In order to improve the safety of the approach, the suicide gene inducible Caspase 9 (iC9) has been included.


Description:

The study will consist of a Phase I, dose escalation phase aimed at evaluating the safety and feasibility of intravenous injections of autologous iC9-GD2-CAR T-cells in patients with refractory/relapsed malignant CNS tumors. Considering the peculiar potential risks associated with the treatment of CNS tumors, the study has been designed to enrol patients in 3 different arms depending on the histology and location of the disease. This model of enrollment is aimed at testing the safety sequentially, starting from categories of patients at lower risk of severe intracranial hypertension first, and subsequently proceeding with patients at proportionally increased risk. In particular, the three arms explored will be relapsed or refractory: - ARM A: MB/other embryonal tumor - ARM B: Hemispheric HGG - ARM C: Thalamic HGG, DMG, DIPG and other rare CNS tumors not included in Arm A and B Eligible patients will undergo leukapheresis in order to harvest T cells, which will be manufactured to obtain the autologous CAR T product iC9-GD2-CAR T-cells, a GD2-targeting CAR T product. Briefly, the patients will be treated with a lymphodepleting regimen containing conventional chemotherapic agents and subsequently will receive a single infusion of GD2-CART01. Moreover, the product contains a suicide gene safety switch (namely inducible Caspase 9): in case of relevant toxicities, the patient will receive the dimerizing agent in order to activate the apoptotic pathway in the infused T cells. After infusion of CAR T cells, the patients will enter a 5-year active follow-up period (for disease follow-up). A conventional 15-year follow-up will be performed as per regulatory requirements in patients receiving gene therapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 54
Est. completion date November 2038
Est. primary completion date November 2027
Accepts healthy volunteers No
Gender All
Age group 6 Months to 30 Years
Eligibility Inclusion Criteria: 1. Imaging assessments performed within 14 days of start of treatment 2. Age: 6months-30years 3. Measurable or evaluable disease on at least 2 dimensions on MRI at the time of treatment enrollment 4. Karnofsky/Lansky=60 5. Recoverfromthetoxiceffectsofpreviousradiationandchemotherapies:grade4and or 3 non-hematologic toxicities must have resolved to grade = 2; in presence of chronic complications (i.e. treatment-associated thrombocytopenia), patient must be clinically stable, according to the opinion of the treating physicians, and meet all other eligibility criteria 6. Positioning of an implantable intraventricular access device (CodmanHolterRickham reservoir, Integra LifeSciences, NJ, U.S.A) and a microdialysis probe (71 high cutoff microdialysis bolt catheter, M Dialysis AB, Stockholm Sweden) 7. Written and signed informed consent from patients, parents or legal guardians. For subjects < 18 year-old their legal guardian must give informed consent. In addition, pediatric subjects will be included in age-appropriate discussion and written informed assent will be obtained for those greater than or equal to 7 years of age, when appropriate 8. Patients of childbearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for four months after receiving the preparative regimen 9. Females of childbearing potential must have a negative pregnancy test because of the potentially dangerous effects on the fetus Exclusion Criteria: 1. Pregnant or lactating women 2. Severe,uncontrolledactiveinfections 3. HIV or active HCV and/or HBV infection 4. Rapidly progressive disease with life expectancy < 6 weeks 5. Historyofgrade3or4hypersensitivitytomurineprotein-containingproducts 6. Hepatic function: inadequate liver function defined as total bilirubin > 4x upper limit of normal (ULN) or transaminase (ALT and AST) > 6 x ULN based on age and laboratory specific normal ranges 7. Renal function: serum creatinine > 3x ULN for age 8. Blood oxygen saturation < 90% 9. Cardiac function: left ventricular ejection fraction lower than 45% by ECHO 10. Marrow function: absolute neutrophils count (ANC) lower than 500/mm3 and/or platelets lower than 20.000 (not reached by transfusion) 11. Congestive heart failure, cardiac arrhythmia, psychiatric illness, or social situations that would limit compliance with study requirements or in the opinion of the principal investigator (PI) would pose an unacceptable risk to the subject. 12.Concurrent or recent prior therapies, before infusion: 1. If receiving glucocorticoids, patient must be on a stable or weaning dose for at least 7 days prior to infusion. Recent or current use of inhaled/topical/non- absorbable steroids is not exclusionary. Subjects receiving steroid therapy at physiologic replacement doses only are allowed provided there has been no increase in dose for at least 2 weeks prior to starting apheresis 2. Systemic chemotherapy in the 3 weeks preceding infusion 3. Immunosuppressive agents less than or equal to 30 days 4. Radiation therapy must have been completed at least 6 weeks prior to enrollment 5. Otheranti-neoplasticinvestigationalagentscurrentlyorwithin30dayspriorto start of protocol therapy 13.Patient-derived GD2-CART01 production failure: vitality <80%, CD3+ cells <80%, CD3+ CAR+ cells <20%, CD3+ CAR+ antitumor activity <60% in functional co-culture assay at an Effector: Target ratio 1:1, viable CAR+ cells upon AP1903 exposition >20%, RCR positivity, Vector Copy Number >10, non-sterility, endotoxin contamination (> 1 EU/ml)

Study Design


Intervention

Biological:
GD2-CART01 (iC9-GD2-CAR T-cells)
Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 6.0 x 106/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells, infused i.v. as a single dose

Locations

Country Name City State
Italy Ospedale Pediatrico Bambino Gesù Roma

Sponsors (1)

Lead Sponsor Collaborator
Bambino Gesù Hospital and Research Institute

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and definition of the MTD/RD To evaluate the safety of the infusion of iC9-GD2-CAR-T cells at different escalating/de-escalating doses and establish the dose limiting toxicity (DLT) and the maximum tolerated dose/recommended dose (MTD/RD) of the cellular product 4 weeks after CAR T cell infusion
Secondary In vivo expansion and persistence To assess the in vivo persistence and expansion of the infused CAR T-cells in the peripheral blood (PB) and CSF using immunoassays and transgene detection (Droplet PCR), both for the whole population and the specific T cells subsets Up to 5 years
Secondary Tumor infiltration To evaluate the tumor infiltration of the infused T cells by immunohistochemistry (IHC), flow cytometry and/or transgene detection (Droplet PCR), whenever the tumor sample is available after the treatment Up to 5 years
Secondary iC9-GD2-CAR-T cells clearance after AP1903 infusion To assess the kinetic of iC9-GD2-CAR-T cells clearance after AP1903 infusion Up to 5 years
Secondary Serum cytokine profiling To define the serum and CSF cytokine profile and its correlation with CRS in order to identify a possible predictive profile Up to 3 months
Secondary Time to progression (TTP) To evaluate the TTP after infusion Up to 5 years
Secondary Event-free survival (EFS) To evaluate the EFS after infusion Up to 5 years
Secondary Overall survival (OS) To evaluate the OS after infusion Up to 5 years
Secondary Disease outcome according to the Response assessment in pediatric neuro-oncology (RAPNO) criteria umor response assessment through the RAPNO criteria Up to 5 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05023551 - Study of DSP-0390 in Patients With Recurrent High-Grade Glioma Early Phase 1
Terminated NCT01902771 - Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors Phase 1
Active, not recruiting NCT02655601 - Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 Phase 2
Terminated NCT03690869 - REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma Phase 1/Phase 2
Completed NCT01466686 - Low Dose Radiation Therapy for Glioblastoma Multiforme Phase 2
Recruiting NCT05212272 - MRI in High-Grade Glioma Patients Undergoing Chemoradiation
Recruiting NCT05925218 - Circulating Tumor DNA Collection From Patients With High Grade Gliomas
Active, not recruiting NCT04911621 - Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma Phase 1/Phase 2
Not yet recruiting NCT06333899 - Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion Early Phase 1
Recruiting NCT04734444 - SonoClear Acoustic Coupling Fluid (ACF) Mimicking Brain Tissue N/A
Completed NCT03775369 - Glioma and Exercising N/A
Completed NCT02022644 - Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma Phase 1
Completed NCT00780819 - Borderzone Sampling N/A
Recruiting NCT06072586 - Study of BDTX-1535 in Recurrent High-Grade Glioma (HGG) Participants With EGFR Alterations or Fusions Early Phase 1
Completed NCT01390948 - A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma Phase 2
Recruiting NCT03952598 - Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy N/A
Recruiting NCT05630664 - Liquid Biopsy in High-grade Gliomas and Meningiomas
Completed NCT01222754 - Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas Phase 1
Recruiting NCT05278208 - Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors Phase 1/Phase 2
Completed NCT03355794 - A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) Phase 1